key: cord-0986244-2t9wsojj
authors: Ciccarelli, Michele; Merciai, Fabrizio; Carrizzo, Albino; Sommella, Eduardo; Di Pietro, Paola; Caponigro, Vicky; Salviati, Emanuela; Musella, Simona; Sarno, Veronica di; Rusciano, Mariarosaria; Toni, Anna Laura; Iesu, Paola; Izzo, Carmine; Schettino, Gabriella; Conti, Valeria; Venturini, Eleonora; Vitale, Carolina; Scarpati, Giuliana; Bonadies, Domenico; Rispoli, Antonella; Polverino, Benedetto; Poto, Sergio; Pagliano, Pasquale; Piazza, Ornella; Licastro, Danilo; Vecchione, Carmine; Campiglia, Pietro
title: Untargeted lipidomics reveals specific lipid profiles in COVID-19 patients with different severity from Campania region (Italy)
date: 2022-08-05
journal: J Pharm Biomed Anal
DOI: 10.1016/j.jpba.2022.114827
sha: 48c37804314bd5a53ac1a953d7659cb4b6d14919
doc_id: 986244
cord_uid: 2t9wsojj

COVID-19 infection evokes various systemic alterations that push patients not only towards severe acute respiratory syndrome but causes an important metabolic dysregulation with following multi-organ alteration and potentially poor outcome. To discover novel potential biomarkers able to predict disease’s severity and patient’s outcome, in this study we applied untargeted lipidomics, by a reversed phase ultra-high performance liquid chromatography-trapped ion mobility mass spectrometry platform (RP-UHPLC-TIMS-MS), on blood samples collected at hospital admission in an Italian cohort of COVID-19 patients (45 mild, 54 severe, 21 controls). In a subset of patients, we also collected a second blood sample in correspondence of clinical phenotype modification (longitudinal population). Plasma lipid profiles revealed several lipids significantly modified in COVID-19 patients with respect to controls and able to discern between mild and severe clinical phenotype. Severe patients were characterized by a progressive decrease in the levels of LPCs, LPC-Os, PC-Os, and, on the contrary, an increase in overall TGs, PEs, and Ceramides. A machine learning model was built by using both the entire dataset and with a restricted lipid panel dataset, delivering comparable results in predicting severity (AUC= 0.777, CI: 0.639–0.904) and outcome (AUC= 0.789, CI: 0.658–0.910). Finally, re-building the with 25 longitudinal (t1) samples, this resulted in 21 patients correctly classified. In conclusion, this study highlights specific lipid profiles that could be used monitor the possible trajectory of COVID-19 patients at hospital admission, which could be used in targeted approaches.

The current pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still delivering an enormous impact on health management globally. Indeed, the scarce vaccination practice in countries with weaker health and economic systems makes COVID-19 still a relevant health and social problem worldwide [1] . While roughly 80% of COVID-19 patients show only mild symptoms, conditions can rapidly evolve to severe phenotype. The pathophysiology of COVID-19 is indeed highly complex; beyond immune changes, metabolism emerged as a critical regulator that is tightly bound to the host response and involved in the disease's progression [2] . Some patients with COVID-19 undergo an altered metabolic state, known as "phenoconversion" [3] , predictive of multi-J o u r n a l P r e -p r o o f organ alteration and poor outcome. Specifically, clinical deterioration in patients with involves multiple pathways, including chemotaxis and interleukin production, but also endothelial dysfunction, the complement system, and immunothrombosis. Indeed, unfavorable outcome in hospitalized COVID-19 patients has been previously associated with changes in concentrations of IL-6, IL-8, IL-10, soluble Receptor for Advanced Glycation End Products (sRAGE), vascular cell adhesion molecule 1 (VCAM-1) and Pentraxin-3 [4] . Moreover, also lipids play various critical biological functions in cellular barriers, signal transduction, material transport, energy storage, cell differentiation, and apoptosis. SARS-CoV-2 can induce characteristic molecular changes detected in patients' sera using proteomic and metabolomic technologies [5, 6] . which also correlates with modification of the inflammatory profile of the COVID-19 patients [7] . Therefore, omic sciences, such as metabolomics and lipidomics, can be instrumental in identifying predictive biomarkers of severity and progression, monitoring the metabolic status of individuals during the time and thus applied to evaluate the metabolic host response to SARS-CoV-2 infection. In this regard, lipids cover a crucial role in numerous metabolic processes, such as energy management and storage, act as structure and membrane components, and are essential players in cell signaling. They have also been found deeply dysregulated in other viral infections, like Ebola virus disease (EVD) [8, 5, 9, 10] .

Lipids are essential also in the life cycle of SARS-CoV-2, which is an envelope virus surrounded by a lipid bilayer, furthermore, following infection, host immune cells like macrophages show a change in lipid metabolism upon activation, which is tightly connected to the immune response to pathogens [11] . Initial studies have in fact evidenced that eicosanoids dysregulation, as well as lower serum HDL levels are connected with disease severity and mortality rate [12, 13] . Therefore lipidomics, with its potential to identify and quantify several lipid subclasses in a single analysis [14] , can be a useful tool for a better comprehension of COVID-19 physiopathology and identification of novel therapeutic strategies. In this regard, targeted [7, 15] and untargeted mass spectrometry-based lipidomics studies [6, 16] have been carried out on different COVID-19 cohorts. All these studies, even if heterogeneous and carried out with different technologies, evidenced a profound dysregulation in plasma lipidome of COVID-19 patients, such as increased sphingomyelins (SM) and reduced diacylglycerol (DG) levels [10] , increased ceramides (Cer) and triglycerides (TG) [9] , and generally decreasing glycerophospholipids [6] even with conflicting results [9, 10] . Overall, lipid biomarkers mirror the severity statuses, but their effective predictive potential has not been clearly identified. Thus, we hypothesize that metabolic changes in COVID-19 patients are earlier than clinical changes and, therefore, potentially exploitable for early prognostic assessment. In this study, to uncover the lipid changes in the plasma of COVID-19 patients, we applied an untargeted J o u r n a l P r e -p r o o f lipidomics approach, by ultra-high-performance liquid chromatography coupled trapped ion mobility mass spectrometry (UHPLC-TIMS-MS), in an Italian cohort of hospitalized COVID-19 patients. We highlight a profound alteration of different lipid subclasses, particularly a significant and progressive decrease of glycerophospholipids, already at the time of admission, and explored the potential capability of a specific lipid subset to predict COVID-19 patients' outcome. 

J o u r n a l P r e -p r o o f Blood samples were collected in fasting states. From each patient, 5-8 mL of whole blood was drawn into EDTA vacutainers and centrifuged at 1,000 × g for 20 minutes at 25°C to separate blood cells and plasma. After collection, plasma samples were aliquoted and stored at -80°C until analysis.

Before extraction, samples were randomized and split in regular sub-groups. Lipids were extracted following the Matyash et al. protocol [17] , with slight modifications: briefly, 20 µL of plasma were 

Univariate and multivariate statistics was performed with MetaboAnalyst 5.0 (https://www.metaboanalyst.ca). Data preprocessing consisted of the following steps: all lipids missing in more than 50% in QCs and 75% in real samples were excluded, furthermore all lipids with a coefficient of variation (CV%) higher than 35% among QCs samples were discarded. In order to flatten the differences between samples and to avoid bias in the statistical analysis, we first normalized lipid intensities with the corresponding deuterated internal standard [19] and then the dataset was log transformed and auto scaled. A preliminary investigation was carried out using confidence (table S1), in this regard, for more than 75% of lipids CV values were < 20%, and for the remaining 25% CV was < 30%. Notably, 91.67% of the annotations were in common between rule based and spectral library approaches, moreover the implementation of trapped ion mobility ensured further confidence in lipid annotation, by comparison of experimental CCS values with those reported in libraries. Following raw data alignment, filtering and annotation as described in sections 2.5, for each lipid feature the precursor ion response was normalized against the class-specific internal standard, as widely reported for untargeted lipidomics approaches [18] . Results were expressed as nmol/mL and reported in supplementary table S4.

In our cohort, no significant differences in baseline characteristics were identified at admission between mild and severe patients. We found a slight prevalence of female patients with no difference of age between mild and severe phenotype. For all the comorbidities analyzed we did not detect a significant difference between the two groups. Furthermore, we subdivided Mild and Severe groups into "survivors" and "non-survivors" considering death as final endpoint. The demographic and comorbidities information are summarized in Table 1 . In the Mild group no demographic and prevalence comorbidities differences were found between "survivors'' and "non-survivors" except for 

The different lipid patterns between the control and COVID-19 group, and in particular, their progression along the phenotypes (from mild to severe), suggests that the lipidome signature (Figure 7) . Several conditions and demographic factors, such as age and comorbidities, predispose to a severe COVID-19 phenotype or even fatal outcome [22] . As indicated in tables 1-3, sex and age represent the only demographic factors within our patient cohort that resulted statistically significant between mild and severe groups.

Thus, we performed a new co-variate using linear models. As reported in the figure S6, this analysis 

COVID-19 evolves rapidly and dramatically, so the identification of early markers capable of predicting the patient's trajectory is essential. The target of our study was to identify a potential lipidomic signature that could mirror the severity and predict the short-term mortality of COVID-19 disease at the time of hospitalization, by using untargeted lipidomics, through the employment of a UHPLC-TIMS-MS approach which adds further confidence to lipid annotation [24] . We found that, among the different lipid classes, glycerophospholipids were the most discriminant between mild and severe conditions as well as with respect to non-COVID-19 patients; in particular several LPCs, LPC-Os and PC-O were the lipids with highest statistical significance, with a progressive decrease in relation to the severity status. Then, we sought if the lipidome signature could be used as a prognostic tool to identify potential progression from mild to severe condition and intra-hospital mortality.

Using the entire dataset, we built a machine learning model that showed reasonable accuracy to predict the disease state. Interestingly, using a restricted panel of six lipids selected across the entire lipid profile, the model showed the comparable results for severity and outcome. COVID-19

pathogenesis is still not completely understood, and lipids play a key role for SARS-CoV2 replication [25] as observed for other human coronavirus infections [26] , suggesting that SARS-CoV2 hijacks the host's lipid metabolism [27, 28] . [16, 7] . With respect to these studies, our findings highlight the significant decrease of LPCs, LPC-Os and PC-Os concentration, which could be an essential aspect to monitor during COVID-19 disease progression. Our data fits with the observations found in Canadian and Brazilian cohorts [29, 30] , both reporting a depressed plasma LPCs profile between COVID-19 and healthy patients. In addition, Sindelar et al. observed of a V-shape trend of LPCs profile after patient recovery from severe status [21] , which fully support the important role of changed lipids profile in our study, across survivors and non-survivors patients.

Furthermore, our data underline that within the entire lipidome signature, not only LPCs, but specifically ether linked lipids such as LPC-Os and PC-Os owns the highest accuracy in discriminating both severity and outcome. Previous Targeted-MS based lipidomics studies were conducted to distinguish between asymptomatic COVID-19 and healthy subjects, or in diagnostics, to discriminate symptomatic COVID-19 and healthy patients, as a new tool to augment RT-PCR strategy [31] . In other studies, with comparable numbers of patients, different proteomic and metabolomic profiles were demonstrated to be associated with clinical phenotypes of COVID-19, from mild to severe [32] . While previous lipidomics studies reported the observation of relative foldchanges of detected lipids between different study groups, the comparison of lipid concentration, is essential to support inter study comparison [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . Nevertheless, only few studies have reported concentration data (as nmol/mL), and hence comparison is not possible. In this regard our data partially agree with results of Berberis et al. [16] , but differences have been observed with available data to the use of different I.S, hence our data could be useful for comparison with future observations or follow-up. Our study, while of relatively small size but comparable to other studies, subjects is relatively small, but comparable in age difference with previous studies which employed as reference group healthy COVID(-) patients [16] [17] [18] [19] [20] [21] . Before the translation to clinical settings, the prognostic value of the identified lipid panel on COVID-19 outcome should be applied to large and separate patients' cohorts,

In 

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Table 2 . Subdivision of COVID-19 Mild patients by outcome in "survivors" and "non-survivors";

CAD: coronary artery diseases; HF: heart failure; PAD: peripheral artery disease; CKD: chronic kidney disease; COPD: Chronic obstructive pulmonary disease. Table 3 . Subdivision of COVID-19 Severe patients by outcome in "survivors" and "non-survivors";

CAD: coronary artery diseases; HF: heart failure; PAD: peripheral artery disease; CKD: chronic kidney disease; COPD: Chronic obstructive pulmonary disease.

Severe "non-survivors" (34) p-value 

☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☒ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Pietro Campiglia reports financial support was provided by Government of Italy Ministry of Education University and Research.

Coronavirus Disease 2019 (COVID-19) in Italy

A metabolic handbook for the COVID-19 pandemic

NMR Spectroscopic Windows on the Systemic Effects of SARS-CoV-2 Infection on Plasma Lipoproteins and Metabolites in Relation to Circulating Cytokines

Clinical features and prognostic factors in COVID-19: A prospective cohort study

Plasma lipidome reveals critical illness and recovery from human Ebola virus disease

Plasma metabolomic and lipidomic alterations associated with COVID-19

Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19

Multi-platform 'Omics Analysis of Human Ebola Virus Disease Pathogenesis

Lipidomic Analysis Reveals Serum Alteration of Plasmalogens in Patients Infected With ZIKA Virus

Alterations of Lipid Profile in COVID-19: A Narrative Review

A lipidomic view of SARS-CoV-2

Lipid metabolism changes in patients with severe COVID-19

Cutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators

Lipidomic Analysis

Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis

Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2

Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics

Untargeted UPLC-MS profiling pipeline to expand tissue metabolome coverage: application to cardiovascular disease

Untargeted metabolomics of COVID-19 patient serum reveals potential prognostic markers of both severity and outcome

Longitudinal metabolomics of human plasma reveals prognostic markers of COVID-19 disease severity

Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension

Impact of sex and gender on COVID-19 outcomes in Europe

Trapped ion mobility spectrometry and PASEF enable in-depth lipidomics from minimal sample amounts

The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target

Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication

Hypolipidemia is associated with the severity of COVID-19

Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis

Metabolomics Profiling of Critically Ill Coronavirus Disease 2019 Patients: Identification of Diagnostic and Prognostic Biomarkers

Covid-19 Automated Diagnosis and Risk Assessment through Metabolomics and Machine Learning

Diagnostic Potential of the Plasma Lipidome in Infectious Disease: Application to Acute SARS-CoV-2 Infection

Proteomic and Metabolomic Characterization of COVID-19 Patient Sera

Comprehensive lipidomics of mouse plasma using class-specific surrogate calibrants and SWATH acquisition for large-scale lipid quantification in untargeted analysis

None